Lexeo Therapeutics, Inc. (LXEO) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Lexeo Therapeutics (LXEO) PT Lowered to $18 at Leerink Partners, 'we continue to see favorable risk/reward into 2H25'
March 24, 2025 10:20 AM EDTLeerink Partners analyst Mani Foroohar lowered the price target on Lexeo Therapeutics (NASDAQ: LXEO) to $18.00 (from $19.00) while maintaining a Outperform rating.
The analyst comments "Todays update is an incremental positive for both clinical programs. PKP2 showed an early clinical signal... More
